MERIL’s Next-Gen Myval THV Series Marks India’s Triumph in Global Heart Valve Sector: Successful Primary Outcomes Unveiled at EuroPCR 2024, Garnering Late Breaking Trial Status and Prestigious Acceptance by The LANCET
Meril Life Sciences’ LANDMARK trial, highlighting the safety and effectiveness of the MyvalTranscatheter Heart Valve Series, stands out as a key late-breaking trial at EuroPCR 2024. The trial involving 768 patients across 31 sites underscores Meril’s dedication to research and patient well-being. Kolkata, 15 May, 2024 – Exciting news from Meril Life Sciences! The LANDMARK trial’s…